Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424746 | 0.89 | F10 (0.77) | F10ALDH1A1ARLMNA | |
| SCHEMBL3426014 | 0.87 | F10 (0.81) | F10ALDH1A1HPGDARSMN1; SMN2 | |
| SCHEMBL3428490 | 0.87 | F10 (0.81) | F10ALDH1A1ARADRB2MAPT | |
| SCHEMBL3426052 | 0.86 | F10 (0.98) | F10ALDH1A1HPGDARSMN1; SMN2 | |
| SCHEMBL3425291 | 0.86 | F10 (0.98) | F10ALDH1A1HPGDARSMN1; SMN2 | |
| SCHEMBL13309764 | 0.85 | F10 (0.72) | F10ALDH1A1ARMEN1KMT2A | |
| SCHEMBL3427505 | 0.85 | F10 (1.00) | F10ALDH1A1HPGDARLMNA | |
| SCHEMBL3424472 | 0.82 | F10 (0.72) | F10TSHRARADRB2 | |
| SCHEMBL3428095 | 0.82 | F10 (0.83) | F10ALDH1A1HPGDARADRB2 | |
| SCHEMBL3426270 | 0.82 | F10 (0.83) | F10ALDH1A1HPGDARMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885TSHR 651/4885ALDH1A1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.